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The development of vaccines for microorganisms and bacterial toxins with the potential to be used as biowarfare and bioterrorism
agents is an important component of the US biodefense program. DVC is developing two vaccines, one against inhalational
exposuretobotulinumneurotoxinsA1andB1andasecondforYersiniapestis,withtheultimategoaloflicensurebytheFDAunder
theAnimalRule.Progresshasbeenmadeinalltechnicalareas,includingmanufacturing,nonclinical,andclinicaldevelopmentand
testing of the vaccines, and in assay development. The current status of development of these vaccines, and remaining challenges
are described in this chapter.
1.Introduction
Certain highly pathogenic microorganisms and their prod-
ucts have the potential to be used as weapons against
either military or civilian populations. The Centers for Dis-
ease Control and Prevention (CDC) classiﬁes these agents
into one of three categories (A, B, or C) according to seri-
ousness of consequences following exposure (http://emer
gency.cdc.gov/agent/agentlist-category.asp; accessed April 7,
2011). The US Department of Defense (DoD) has a long
history of developing therapeutics and prophylactics (vac-
cines) to protect the warﬁghter against oﬀensive use of these
agents. Until relatively recently, these countermeasures could
beusedunderaninvestigationalnewdrugapplication(IND)
mechanism. Now, the DoD mandates that any such products
administered to the US warﬁghters be licensed by the US
Food and Drug Administration (FDA). Currently, DVC is
developing two vaccines for DoD’s Joint Vaccine Acquisition
Program (JVAP); these include a recombinant vaccine to
protect against fatal botulism following inhalational expo-
sure to the A1 and B1 serotypes of botulinum neurotoxin
(rBV A/B), as well as a recombinant vaccine to protect
against pneumonic plague following inhalational exposure
to Yersinia pestis (Y. pestis) (rF1V). The speciﬁc performance
and regulatory requirements, progress, challenges, and suc-
c e s s e si ne a c hp r o g r a ma r er e v i e w e db e l o w .
2. DiseaseCharacteristics
2.1. Botulism. Botulism is caused by neurotoxins produced
by the bacterium Clostridium botulinum (C. botulinum), and
disease presents in diﬀerent forms including infant, wound,
adult colonization, and foodborne botulism [1]. The clinical
picture is due to cholinergic inhibition, and characteristic
signs include a descending muscle weakness, dry mouth, dif-
ﬁculty swallowing, slurred speech, double or blurred vision,
and drooping eyelids. The botulinum neurotoxin (BoNT)
eventually causes paralysis of the respiratory muscles, which
prevents unassisted respiration and leads to death in a short
time. Exposure to aerosolized BoNT leads to another form of
disease, known asinhalational botulism, whichpresentswith
similar symptoms [2]. Currently, the only points of reference
for human lethality following inhalational intoxication are
estimates based on DoD modeling and extrapolation from
nonhuman primate (NHP) studies (both based on mass of
BoNT/70kg of body weight) and blood levels of BoNT
achieved in foodborne cases of botulism. Estimates of hu-
man lethality of BoNT serotype A by intramuscular (IM)2 Advances in Preventive Medicine
exposure are within the range of 0.09 to 0.15μg/70kg
bodyweight and from 0.7 to 0.9μg/ 70kg bodyweight by
inhalation based on extrapolation from NHP studies [2, 3].
Published estimates of human lethality of BoNT serotype B
are not available. The BoNT levels in the sera of patients with
botulismareusuallylessthan10mouseintraperitoneallethal
dose 50% (MIPLD50)/mL [2].
Treatment of botulism cases in the USA usually consists
ofadministrationofequineantitoxinantiseraandsupportive
care. The equine antitoxins include a licensed bivalent and
monovalent antitoxin that contains neutralizing antibodies
against BoNT types A/B and E, respectively, and an investi-
gational heptavalent (ABCDEFG) antitoxin. The heptavalent
botulinum antitoxin (HBAT, Cangene Corporation) is avail-
able through a CDC-sponsored IND protocol. Following
expirationofthebivalentandmonovalentproductsinMarch
2010, HBAT became the only botulinum antitoxin available
intheUSAfornaturallyoccurringnoninfantbotulism.Cases
of infant botulism are treated with the recently licensed
BabyBIG which is derived from the blood of human donors
vaccinated with a pentavalent (ABCDE) toxoid vaccine. In
NHPs exposed to lethal challenge, treatment is only eﬀective
when administered within 18 to 36 hours of exposure.
2.2. Plague. Plague is a zoonotic infection with Y. pestis
that is normally transmitted from rodents to humans
when humans are bitten by infected ﬂeas. There are three
manifestations of the disease, with ﬂea bites usually causing
the bubonic form in which a painful swelling (bubo) of
the draining lymph nodes occurs [4, 5]. Left untreated, the
infection will cause sepsis and death in approximately half
of the cases. Bubo formation is not present in the second
form of disease, which leads directly to sepsis, and occurs in
about a third of the cases. Bubonic and septicemic infections
occasionally progress to secondary pneumonic infections.
Infection with Y. pestis also rarely occurs through inhalation
of the organism, and, after 1 to 6 days, the disease manifests
in its pneumonic form, which is nearly always fatal unless
the patient is treated with antibiotics within 20 hours of
symptom onset [6], and spreads from person to person by
respiratorydropletsformedduringcoughing[7–11].Clinical
signs include fever with cough and dyspnea, and there may
be production of bloody, watery sputum. Nausea, vomiting,
abdominal pain, and diarrhea may also be present.
Other than early diagnosis and treatment of plague
with antibiotics, which are essential to survival, there is no
licensed plague vaccine available in the United States. The
production of a killed, whole-cell plague vaccine (formalin-
inactivated Y. pestis), previously licensed as Plague Vaccine
United States Pharmacopoeia, was discontinued in 1999.
Moreover,thatvaccinewasnoteﬀectiveinpreventingagainst
primary pneumonic plague.
3. DoD Vaccine Performance Requirements
There is a need for vaccines that can protect against
respiratory exposure to botulinum neurotoxins and plague.
Development of these vaccines by DVC is guided by the DoD
performance requirements and demonstration of eﬃcacy in
accordance with the Animal Rule (21 CFR 601.91 Subpart
H, “Approval of Biological Products When Human Eﬃcacy
Studies Are Not Ethical or Feasible”).
T h ep e r f o r m a n c eo fD o Dp r o d u c t si sb a s e do nu s e r
requirements provided in a Capability Development Doc-
ument (Table 1). For the two vaccines described in this
paper, the key performance parameter is FDA licensure. All
other requirements are characterized as either threshold (i.e.,
the absolute minimum acceptable level of performance) or
objective (the characteristics that are considered to be ideal).
Table 1 lists some of these characteristics for the rBV A/B
and rF1V vaccines. These requirements form the basis for
assessing the product during its development.
GiventhatFDAlicensureistheultimatekeyperformance
parameter for DoD’s medical countermeasures, the overall
life cycle development plan is not dissimilar to products
under development by the private sector. However, DoD
products must also be developed in accordance with acqui-
sition regulations (Federal Acquisition Regulation, Defense
Federal Acquisition Regulation Supplement, and others). In
addition, these programs are subject to defense funding
which is not always as ﬂexible as might be the case with
commercial development.
4. Regulatory Strategy: The FDA AnimalRule
Licensure of the rBV A/B and rF1V vaccines will use
the FDA Animal Rule. The Animal Rule was established
by the FDA to allow development and licensure of pro-
ducts that could not otherwise be licensed using traditional
eﬃcacy testing. The Animal Rule may be used for li-
censure when eﬃcacy studies are unethical due to high path-
ogenicity, and disease is rare enough in nature that ﬁeld
studies would be either impossible or at least imprac-
tical(http://www.fda.gov/OHRMS/DOCKETS/98fr/053102a
.htm; accessed April 7, 2011).
The four major requirements of the FDA’s Animal Rule
a r ea sf o l l o w s :
(i) Requirement no.1: There is a reasonably well-
understood pathophysiological mechanism of toxic-
ity of the substance and its prevention or substantial
reduction of this toxicity by the product.
(ii) Requirement no.2: The eﬀect is demonstrated in
more than one animal species expected to react
with a response predictive for humans, unless the
eﬀect is demonstrated in a single animal species that
represents a suﬃciently well-characterized animal
model for predicting the response in humans.
(iii) Requirement no.3: The animal study endpoint is
clearly related to the desired beneﬁt in humans,
generally the enhancement of survival or prevention
of major morbidity.
(iv) Requirement no.4: The data or information on the
kinetics and pharmacodynamics of the product or
other relevant data or information, in animals orAdvances in Preventive Medicine 3
Table 1: Required performance parameters for the rBV A/B and rF1V vaccines.
Key Performance Parameter: FDA Licensure
Performance attribute Development threshold Development objective
rBV A/B rF1V rBV A/B rF1V
Eﬃcacy Protect 80% of immunized persons Protect 90% of immunized persons
Immune response
An immune response suﬃcient to meet
threshold eﬃcacy requirements for this
vaccine within 210 days of the initial vaccine
dose
An immune response suﬃcient to meet
threshold eﬃcacy requirements for this
vaccine within 30 days of the initial vaccine
dose
Duration of protection Protection for at least one year from
completion of the primary vaccination series
Protection for ﬁve years after the
administration of a single-dose vaccine
Number of doses to achieve
protection (primary series)
31
Shelf life 1 year 5 years
R and D Preclinical FDA
approval
Phase 4
Phase 1 Phase 2 Phase 3
IND BLA
Animal rule—nonclinical
eﬃcacy studies
Figure 1: Stages of the advanced development of vaccines. The stages shown in dark grey are common to traditional and FDA’s Animal Rule
licensure; the additional nonclinical studies are shown in light grey.
humans, allows selection of an eﬀective dose in
humans.
As of July 2011, no vaccine has been approved by the
FDA under the FDA Animal Rule, so the length of time
and costs associated with obtaining approval have yet to
be determined. Traditional licensure may take 15 years
from discovery to approval; approval of vaccines by the
FDA Animal Rule may take longer due to the additional
nonclinical requirements (Figure 1) and the need to develop
and characterize the animal models and challenge systems.
5.Development ofthe rBVA/Band
rF1VVaccines
The rBV A/B and rF1V vaccine candidates were initially
developed at the US Army Medical Research Institute for
Infectious Diseases (USAMRIID). They were transferred
to JVAP (and subsequently to DVC) in an early stage of
development. The target indication of these vaccines is
protection of adults 18 to 55 years of age from disease caused
by inhalational exposure to BoNT/A1, BoNT/B1, or Y. pestis.
The rBV A/B vaccine candidate [12] comprises the
recombinant 50kDa carboxy-terminal of the heavy chains
of Antigen A and Antigen B expressed individually from
Pichia pastoris using a methanol induction system. Antigen
A is derived from the BoNT/A1 expressed by C. botulinum
strain NCTC 2916 (group I, proteolytic), and Antigen B
is derived from BoNT/B1 expressed by C. botulinum strain
Danish (group I, proteolytic). Antigen A was modiﬁed to
prevent proteolytic cleavage at the N-terminus during gene
expressionbyremovingthecodonscodingforproteolytically
susceptible amino acids. Each 0.5mL dose of rBV A/B-40
consists of a 1:1 mixture of 20μg Antigen A and 20μgA n -
tigen B adsorbed to Alhydrogel.
The rF1V vaccine candidate for plague [13]c o m p r i s e s
the F1 capsular protein and the V virulence protein of Y.
pestis Colorado 92 (CO92) fused into a single protein, which
is produced in Escherichia coli (E. coli)a n df o r m u l a t e dw i t h
Alhydrogel.
For any product, successful progress towards licensure
involves the integration of diﬀerent functional groups to
develop a scalable manufacturing process from the research
and development (R&D) proof-of-concept, coordinate the
logistics between the release of manufactured material
suitable for testing, and stage the appropriate nonclinical,
and clinical studies. The progress of the rBV A/B and rF1V
vaccines is described below for manufacturing, nonclinical
and clinical eﬀorts.
5.1. Manufacturing Processes. The rBV A/B and rF1V vac-
cines were initially developed at USAMRIID and were
transferred to advanced development at the stage indicated
by the gray arrows in Figure 2. The black arrows indicate
the stage of manufacturing development for each product.
The products successfully overcame the following challenges
to advance to this stage of manufacturing: (1) technology
transfer to a contract manufacturing organization and
processredesignduetoequipmentchanges,(2)development
of manufacturing methods that support the production of4 Advances in Preventive Medicine
Process validation activities Clinical phase Supporting activities
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3
Initial development
• Molecule selection
• Host cell system selection
• Fermentation process development
• Harvest development
• Puriﬁcation development
• Virus/impurity clearance
• Formulation development
• Selection raw materials
Initial Development
• Analytical method development
• Product characterization
• Initial stability testing/proﬁle
• Establish prelim reference standard
• Initial product technical speciﬁcation
•Scaleup
• Process characterization
• Virus/impurity clearance (scaleup)
• Establish process deﬁnition
Process veriﬁcation
• Validation plan and protocols
• Process risk assessment
• Small-scale model qualiﬁcation
• Small-scale veriﬁcation
• Process intermediate stability
• Process solution stability
• Large-scale veriﬁcation
• Cleaning validation
• Extractable/leachable study
• Manufacturing conformance lots
(commercial performance qualiﬁcation)
Continuing development and optimization
• Assay qualiﬁcation
• Establish product characterization
• Establish interim reference standard
• Revised product technical speciﬁcation
• Additional stability testing/proﬁle
Continual veriﬁcation
• Manufacturing commercial lots
• Process knowledge
• Control updates
Continual veriﬁcation
• Establish monitoring program (trending)
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Continuing development and optimization
• Assay validation
• Establish primary reference standard
• Revised product technical speciﬁcation
• Additional stability testing/proﬁle
• Establish initial shelf life (expiration date)
rF1V
rBV A/B
rF1V
rBV A/B
rF1V
rBV A/B
•
Process optimization
• Engineering and CGMP lot(s)
• Engineering and CGMP lot(s)
Identiﬁcation of critical, key, and
noncritical process parameters
Licensure
Submit IND
Figure 2: Stages of the manufacturing process, product transition to DVC (grey arrows), and current status (black arrows) of the
development eﬀorts for rF1V and rBV A/B vaccines. Some activities may be conducted concurrently.
clinicaltrialmaterialandcanbevalidated,(3)scale-upissues
associated with either an increase in the number of required
troop equivalent doses or nonscalable technological steps,
(4) developing needed reagents and analytical methods for
product quantitation, purity, and process impurities, and
(5) determining conditions that support product stability
throughout the manufacturing process.
The Pichia pastoris master and working cell banks for the
Antigen A and Antigen B expression strains used to produce
the rBV A/B vaccine were generated by expanding accession
cell banks produced for each antigen and characterized
for purity, identity, and suitability according to the FDA
and International Conference on Harmonisation (ICH)
guidance. Antigen A and Antigen B are manufactured and
adsorbed to Alhydrogel separately and then combined to
form the ﬁnal formulated bulk vaccine. The manufacturing
process is at commercial scale (100L for Antigen A and
600LforAntigen B).Current GoodManufacturingPractices
(CGMP) ﬁll/ﬁnish activities were conducted at a 5,000vial
level to support the Phase 1B and Phase 2 clinical trials.
Currently the formulated FDP manufacturing process is
being scaled to the full commercial scale (approximately
300,000vials/lot).
The fused rF1V protein comprising the F1 capsular
p r o t e i na n dVv i r u l e n c ep r o t e i no fY. pestis is produced
in E. coli and formulated with the adjuvant Alhydrogel.Advances in Preventive Medicine 5
The sequence encoding the rF1V antigen was derived from
plasmid pPW731 produced at USAMRIID [13]a n dw a s
initially expressed from pT5.F1V.1 cell banks but later
transitioned to expression from pPW731 cell banks due to
intellectual property constraints. Both expression systems
use the same regulatory elements for gene expression and
the same antibiotic resistance gene for plasmid maintenance.
The cell banks were characterized for purity, identity, and
suitability according to the FDA and ICH guidance. The
manufacturing process was scaled to a ﬁnal commercial
process, which is 1,500L (working volume for fermentation)
and 500L puriﬁcation scale.
Clinical lots for each vaccine were manufactured and
released for use in the completed Phase 1 and the ongoing
Phase 2 trials, described below. A stability program is
ongoingandwasdesignedtoestablish,maintain,andexecute
a testing strategy that is compliant with the FDA and ICH
guidance.
5.2. Nonclinical Studies to Support the Animal Rule Require-
ments. Animal models are critically important for FDA’s
Animal Rule licensure, in that they are used to assess vaccine
eﬃcacy, and the vaccine-induced animal immune responses
arecomparedtohumanimmuneresponsestopredictclinical
beneﬁt. The “Draft Guidance for Industry-Animal Models-
Essential Elements to Address Eﬃcacy Under the Animal
Rule” released in 2009 was followed to guide the design
and execution of nonclinical studies. The nonclinical plans
are integrated with the clinical development plans for each
vaccine to support the comparison of immune responses
across species and to enable the selection of the appropriate
human dosage.
The animal studies described below were conducted
at accredited facilities under the oversight of an assigned
Study Director and attending veterinarian and performed
according to the Institute- and the DoD-approved animal
protocols. Every eﬀort was made to minimize the suﬀering
and distress of animals exposed to challenge agents or
subjected to procedures, using approved anesthetics (1 to
6mg/kg Telazol for macaques and isoﬂurane for mice).
Biostatisticians were consulted in the study design phase
to ensure the study used the proper number of animals
needed to achieve interpretable data. Animals were observed
multiple times per day for signs of clinical illness during
the in-life phase. Macaques were anesthetized and humanely
euthanizedwithanoverdoseofaeuthanasiaagentcontaining
pentobarbital when meeting preapproved euthanasia criteria
such as decreased body temperature to <93.0◦F, >20%
loss of body weight from prechallenge weight, respiratory
distress/failure, signiﬁcant reduction in activity (e.g., unable
torightitself,completelackofactivity,persistentprostration,
or total paralysis), or signs of pneumonia. Mice were euth-
anized using CO2 gas, and guinea pigs were euthanized by
a barbiturate overdose injected intraperitoneally or directly
into the heart after the animals were anesthetized.
Proof-of-concept studies conducted by USAMRIID
using research material and pilot lots demonstrated the
immunogenicity and eﬃcacy of rBV A/B and rF1V vaccines
in a variety of animal models including rodents and NHPs.
The nonclinical development plans for rBV A/B and rF1V
continue the testing in stages: (1) performing initial toxicity
studies to support the clinical development, (2) developing
and characterizing aerosol challenge models, (3) identifying
vaccination regimens that induce immune responses sim-
ilar to the responses observed in clinical volunteers, (4)
demonstratingeﬃcacyinanimalmodels,and(5)conducting
ﬁnal pivotal vaccination/aerosol challenge and reproductive
toxicity studies.
GoodLaboratoryPractice-(GLP-)compliantnonclinical
safety studies were conducted to support clinical testing of
the rBV A/B and rF1V vaccines. These evaluated general
toxicity following repeat-dose administration in mice and
local reactogenicity of administration of a full human dose
of vaccine in rabbits. An additional study to evaluate
neurobehavioral toxicity was performed for the rBV A/B
vaccine.Thevaccinesproducednoapparentsystemictoxicity
and only mild inﬂammation at the injection site. The rBV
A/B vaccine produced no apparent neurobehavioral toxicity.
Together these nonclinical studies supported the initiation of
Phase 1 clinical trials.
An important aspect of developing animal models is
the requirement for well-characterized challenge agent. The
challenge agents used in the nonclinical eﬃcacy studies
are classiﬁed as Category A Select Agents by the CDC,
and all US facilities that possess or transfer the challenge
agent must be registered with the CDC and/or the US
Department of Agriculture. The BoNT/A1 and BoNT/B1
were fully characterized to conﬁrm their identity, purity,
and strength (biological activity or potency). Protein con-
centration and biological activity (in terms of MIPLD50
units) of both BoNTs were veriﬁed using a micro-Bradford
protein assay and mouse (toxin) potency assay, respectively.
Testing protocols were established to monitor the real time
and accelerated stability of the vialed BoNTs. The stability
program includes annual testing to conﬁrm the maintenance
of strength and purity using the micro-Bradford protein
assay, mouse (toxin) potency assay, SDS-PAGE, and size
exclusion chromatography.
The rF1V challenge studies use the CO92 or C12
strains of Y. pestis. To ensure the quality and integrity of
these strains, challenge material is grown, characterized,
and stored in a three-tiered banking system. The banks
are characterized by (1) purity on selective media, (2)
titer, (3) phenotype, (4) Gram stain, (5) polymerase chain
reaction (PCR) for presence of plasmids and chromosomal
marker (pathogenicity island), (6) nitrate reduction, (7)
antibiotic susceptibility, (8) growth curve, and (9) glycerol
fermentation.
The ﬁrst requirement of the Animal Rule relates to
understanding the pathophysiologic mechanism of toxicity
and demonstrating that the pathology is similar to that
in humans. This is a signiﬁcant challenge, especially when
there is little information available for human disease (e.g.,
inhalational botulism). Usually studies in two animal species
are required for this purpose, unless the disease is well
characterized in one animal species and is an accepted
model for the human disease. For the rBV A/B and rF1V
vaccine development programs, rodent and NHP models6 Advances in Preventive Medicine
Table 2: Symptoms following aerosol exposure to BoNT/A1 or BoNT/B1.
Symptoms Human1
NHP
(rhesus
macaque)
Guinea pig
(Hartley)
Mouse
(CD-1)
NHP
(rhesus
macaque)
Guinea pig
(Hartley)
Mouse
(CD-1)
Inhalational BoNT/A1 Inhalational BoNT/B1
O n s e to fs y m p t o m s :
dose dependent Yes Yes Yes Yes Yes Yes Yes
Lethargy Yes1 Yes Yes NR Yes Yes NR
Flaccid paralysis Yes NR Yes Yes NR NR Yes
Ptosis (drooping
eyelids) Yes Yes Yes Yes Yes Yes No
Dysphagia (diﬃculty
swallowing) Yes1 Y e sN RN RY e sN RN R
Symmetric,
descending paralysis Yes Yes NR Yes Yes NR NR
Labored respirations NR2 Yes Yes Yes Yes Yes Yes
Ataxia Yes1 Y e sN RN RY e sN RN R
Muscle weakness Yes1 Yes Yes Yes Yes Yes Yes
Lateral recumbency NR Yes NR NR Yes NR NR
Nasal discharge No Yes No? NR Yes Yes No
Constipation Yes Yes NR NR NR NR NR
Paresis Yes Yes Yes Yes Yes Yes NR
Coughing No Yes NR NR Yes No NR
Piloerection NR NR Yes Yes NR Yes Yes
Lethality Yes Yes Yes Yes Yes Yes Yes
Time to death: dose
dependent NR Yes Yes Yes NR NR NR
1Speciﬁc observations in humans following inhalational exposure.
2NR, not reported.
were developed to evaluate disease pathophysiology fol-
lowing inhalational exposure of BoNTs and Y. pestis.T h e
comparisons of the animal hallmarks of disease to what is
known for humans are presented in Tables 2 and 3.
The lethality of BoNT/A1 and BoNT/B1 was determined
in CD-1 mice and guinea pigs (unpublished) and recently
in rhesus macaques [14]. A stage-wise approach was used to
estimate the inhaled median lethal dose (LD50)a n de x p o s u r e
concentration (LCt50). The pathophysiologic responses to
a e r o s o le x p o s u r ew e r ee v a l u a t e df o re a c hs p e c i e st oi d e n t i f y
relevant endpoints for eﬃcacy studies. The most relevant
pathophysiological responses in mice and rhesus macaques
weremortalityanddevelopmentofclinicalsignsofbotulism.
Clinical observations in all species were consistent with
the recognized pattern of botulism disease progression in
humans (Table 2). A signiﬁcant dose response was observed
with regard to lethality and the onset and duration of clinical
signsineachspecies.Nosigniﬁcantchangesinclinicalhema-
tology and chemistry and gross and microscopic pathology
were observed in mice or rhesus macaques. Changes in
physiologic parameters measured by telemetry in rhesus
macaques also did not correlate with mortality.
ThepathologyinducedbyY. pestis CO92wasevaluatedin
animals through clinical chemistries, hematology, telemetry
cynomolgusmacaques(CMs)only,anddetailedhistopathol-
ogy in Swiss Webster mice and CMs. Exposed animals
demonstrated multilobar pneumonia, bacterial inﬁltration
of macrophages and lymphoid tissues, fever, sepsis, and
death. Data collected from the mouse model development
studies estimated the LD50 of CO92 to be approximately
2,000 colony-forming units (cfu).
In the CMs, the inhaled dosage was calculated using
the total accumulative tidal volume as measured by plethys-
mography [15]. The LD50 was estimated to be 24cfu
by Probit analysis. Telemetry provided useful information
on the clinical course of disease not captured by clinical
observations. A rise in temperature routinely coincided
with the loss of diurnal rhythm, while increased heart and
respiration rate followed by inactivity strongly correlated
with a lethal outcome. All CMs with Y. pestis positive blood
cultures died from pneumonic plague. The pathology in the
lungs of all CMs was consistent with the pathology observed
in pneumonic plague described in humans. The signiﬁcant
ﬁndings are compared across the species in Table 3.
5.3.IdentiﬁcationofVaccinationRegimensandDemonstration
of Eﬃcacy in Animal Models. The second requirement of the
Animal Rule relates to demonstrating that the responses toAdvances in Preventive Medicine 7
Table 3: Clinical signs, gross pathology and histopathology associated with plague infection1.
Symptom or lesion Human Historical
CM
DVC SW
mouse DVC CM
Lymphadenopathy Yes Yes Yes Yes
Fever Yes Yes ND Yes
Malaise Yes Yes Yes Yes
Lethargy Yes Yes Yes Yes
Elevated pulse Yes Yes ND Yes
Cyanosis Yes (late) Yes ND ND
Pharyngitis Yes Yes ND ND
Cough Yes ND ND Yes
Rales Yes Yes ND ND
Sepsis Yes Yes Yes Yes
Gross pathology primary pneumonic plague
Fibrinous pleuritis Yes ND ND Yes
Pneumonia Yes Yes Yes Yes
Mediastinal hemorrhage Yes Yes ND Yes
Congestion of trachea/bronchi Yes Yes Yes Yes
Histopathology primary pneumonic plague
Pulmonary congestion Yes Yes Yes Yes
Necrohemorrhagic foci Yes Yes Yes Yes
Fibrinous pleuritis Yes Yes ND Yes
Disseminated intravascular
coagulation Yes Yes ND ND
Neutrophil inﬁltration of lung Yes Yes Yes Yes
Bacteria in lung Yes Yes Yes Yes
Mediastinitis Yes Yes Yes Yes
Bacteria in spleen Yes Yes Yes Yes2
1Modiﬁed from information contained in Adamovicz and Worsham [16].
CM: cynomolgus macaque, ND: not determined, SW: Swiss Webster.
2Bacterial burden not quantitated.
the countermeasuresare similar in animals and humans. The
third requirement is to demonstrate the same endpoint in
animals that is expected for humans given the vaccine. For
the rBV A/B and rF1V vaccines, that endpoint is survival.
The rBV A/B program vaccinated NHPs with the same
material administered to healthy adults in clinical trials and
followed the vaccination schedule used for humans. An
abbreviated schedule was used for the mice. Neutralizing
antibody responses to BoNT/A1 and BoNT/B1 in CD-1
mice and rhesus macaques were evaluated across various
vaccine dosages and compared to the neutralizing antibody
responses observed in the clinical trial volunteers. Dosages
inducing similar antibody levels were identiﬁed for both
animal models and will be used in pivotal animal studies
using the Phase 3 clinical material.
Initial eﬃcacy studies in rhesus macaques demonstrated
protection from aerosol challenge using the identiﬁed vac-
cination regimen. The protective eﬃcacy of the antibody
levels induced in humans was assessed using passive transfer
studies. A guinea pig passive transfer model was developed
and used to demonstrate the protective eﬃcacy of puriﬁed
immunoglobulin from human rBV A/B vaccinees [17].
A similar approach was used for the rF1V program. Vac-
cine dosage titration studies in CMs and mice are in progress
using the material used in the Phase 2b clinical trial to assess
the immune responses and eﬃcacy. The ﬁrst objective is to
evaluate survival across ﬁve vaccine dosages to select vaccine
dosages for use in follow-on studies. The secondary objective
is to collect serum from animals in all groups for evaluation
in passive transfer studies and to determine the antibody
titers in Bridge ELISA (described in more detail below).
The follow-on study is designed to conﬁrm the minimum
protective dosage of vaccine and estimate the minimum level
of antibody in rF1V-vaccinated animals that correlates with
s u r v i v i n ga e r o s o le x p o s u r et oY. pestis CO92.
A mouse passive transfer model was developed to assess
the ability of immune sera to provide protection from an
aerosol challenge. Sera from CMs or human volunteers
vaccinatedwithrF1Vweretestedinthemodelandtheresults
described [18]. A deﬁnitive correlation between survival in
CMs and an antibody level remains to be determined.8 Advances in Preventive Medicine
Table 4: Vaccine program status for meeting the requirements of the FDA Animal Rule.
Animal Rule rBV A/B rF1V
Requirement 1: well understood
pathophysiology and amelioration
The published literature has shown that
generation of neutralizing antibodies
against BoNT provides protection against
inhalational botulism.
The published literature has shown that
the F1 and V antigens from Y. pestis can
provide protection from pneumonic
plague.
Pathophysiology following aerosol
exposure of CD-1 mice and rhesus
macaques is comparable to the
pathophysiology of disease in humans.
Pathophysiology following aerosol
exposure of Swiss Webster mice and CMs
is comparable to the pathophysiology of
disease in humans.
Vaccination with rBV A/B elicits a
humoral immune response in mice and
macaques that provides protection
against exposure to aerosolized
neurotoxins.
Vaccination with rF1V elicits a humoral
immune response in mice and macaques
that provides protection against exposure
to aerosolized Y. pestis.
Requirement 2: eﬀect is demonstrated in
more than one species
The mouse and macaque models have
immune responses to vaccination with
rBV A/B that are similar to the response
in humans. Data obtained to date
indicate that vaccination induces
neutralizing antibody titers believed to be
protective in tested species.
The Swiss Webster mouse and
cynomolgus macaque models have
immune responses to vaccination with
rF1V that are similar to the response in
humans. Data obtained to date indicate
that antibody titers to F1 and V are
induced in tested species.
Requirement 3: the animal study
endpoint is related to the desired beneﬁt
in humans
Nonclinical eﬃcacy study endpoints
measure survival against an aerosol
challenge, which is the desired beneﬁt in
humans.
Nonclinical eﬃcacy study endpoints
measure survival against an aerosol
challenge, which is the desired beneﬁt in
humans.
Requirement 4: data allows selection of
an eﬀective dose in humans
The mouse toxin-neutralizing antibody
assay (MNA) provides a species-neutral
assay for quantitating the level of
neutralizing antibodies.
The Bridge ELISAs are in development as
species-neutral assays that permit direct
comparison across samples from diﬀerent
species.
The neutralizing antibody concentration
(NAC) determined by the MNA is under
evaluation as a correlate of protection.
Bridge ELISA, macrophage cytotoxicity
assays, and passive transfer studies are
under evaluation for correlation with
protection.
Passive transfer assesses the protective
capacity of antibodies present in vivo at
the time of aerosol challenge. This is
under development as a model to assess
the protective capacity of transferred
immunoglobulin from human vaccines.
Passive transfer assesses the protective
capacity of antibodies present in vivo at
the time of aerosol challenge. This is
under development for consideration as a
model to assess the protective capacity of
transferred serum from human vaccines.
The approach taken to meet the Animal Rule require-
ments is summarized in Table 4 for the rBV A/B and rF1V
vaccines and described in more detail below. Brieﬂy, the
animal models with similar disease characteristics to those
observed in exposed humans are being used to assess the
immune responses and eﬃcacy induced by vaccination. The
status of progress to date for the speciﬁc requirements is
indicatedinTable 4.Thedesignsandstatisticalanalysisplans
forthepivotalGLPnonclinicaleﬃcacystudieswillneedtobe
prepared and discussed with the FDA. The objective of these
studieswillbetogeneratedatathatsupportstheAnimalRule
requirements to demonstrate eﬃcacy and to extrapolate a
dosage likely to produce clinical beneﬁt in humans. These
studies will use the Phase 3 clinical trial material, and
reproductive toxicity will be assessed concurrently.
5.4. Clinical Testing and Human Safety. The rBV A/B and
rF1V vaccine candidates were (or are being) tested in the
Phase 1 and the Phase 2 clinical trials. All clinical trials
were evaluated by a Scientiﬁc Merit Review Board consisting
of independent experts and approved by an independent
Investigational Review Board and the US Army’s Human
Research Protections Oﬃce. The studies were managed by a
contracted clinical research organization. Safety was moni-
tored continuously by independent physicians and overseen
by a Data Safety Monitoring Board (DSMB). All studies were
conducted in accordance with the current Good Clinical
Practice as required by applicable US federal regulations (21
CFR Parts 50, 56, and 312) and the ICH guidelines.
Male and female volunteers were recruited and assessed
for eligibility after signing an informed consent form.
Subjects had to be healthy, as determined by standard
screening assessments including medical history, physical
examination, and laboratory tests (hematology, chemistries,
and urinalysis). For rBV A/B trials, subjects with a history
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therapy with botulinum toxin were excluded. In trials for
both vaccines, subjects with a history of use of immuno-
suppressive drugs, including glucocorticoids, and recent
vaccinationswereexcludedfromthestudy.Studyvaccinewas
administered as a 0.5mL IM injection in the deltoid muscle.
Safety monitoring consisted of collection of injection site
and systemic reactogenicity data in a volunteer diary via
an interactive voice response system after vaccination, and
assessment of treatment emergent adverse events (TEAEs)
at scheduled and ad hoc visits, if needed, throughout the
study. Injection site reactions (local reactions) were deﬁned
as pain, tenderness, pruritus, redness/erythema, other rash,
and swelling or induration. Prespeciﬁed systemic reactions
included fever, fatigue, myalgia, headache, nausea, vomiting,
and diarrhea. Any other system organ manifestation was
also to be recorded and evaluated as an adverse event (AE).
Grading of AEs was performed by study-speciﬁc adaptation
of the most up-to-date FDA guidelines for toxicity grading
in preventive vaccine clinical trials. Any abnormal laboratory
value, abnormal vital sign, or abnormal physical ﬁnding that
was considered clinically signiﬁcant by the investigator or
met the grading criteria for toxicity of Grade 1 or higher was
reported as an AE.
5.5. Clinical Trials for rBV A/B. The rBV A/B vaccine was
evaluated in adults (18–45 years) in two Phase 1 (rBV A/B-
01 and rBV A/B-01B) and one Phase 2 (rBV A/B-02) clinical
trials (unpublished). Blood was collected to determine the
NAC to BoNT/A1 and BoNT/B1 using the MNA at pre-
determined intervals during the study and for calculation of
the seroconversion rate. Blood was also collected for passive
transfer studies for evaluation of eﬃcacy in animals.
The ﬁrst trial, rBV A/B-01, was a single-center, open-
label, dosage-escalation study designed to evaluate the safety,
tolerability, and immunogenicity of a two-dose regimen
(Days 0 and 28) of rBV A/B given at three ascending dosages
(10μg, 20μg, and 40μg total immunizing protein with
adjuvant) and an unadjuvanted antigen-only formulation at
the 40μg total immunizing protein. Forty-four volunteers
participated in this study, with 11 in each of the 4 treatment
cohorts. The second study, rBV A/B-01B, was a follow-on
study to evaluate formulated vaccine administered at two
dosages (40μg and 100μg total immunizing protein) using
four diﬀerent three-dose schedules (Days 0, 28, 56, Days 0,
28, 112 or Days 0, 28, 182, or Days 0, 56, 182). The addition
of a third vaccine dose in the Phase 1B study was expected
to increase the level and duration of the immune response.
Eighty volunteers participated in this study (10 volunteers
per vaccination cohort, 40 volunteers per dosage group).
Dose escalation to the higher dosage occurred after a review
by the DSMB of all safety data in both studies.
The majority of volunteers experienced at least one
TEAE, and most AEs were mild to moderate in intensity
and self-limited in both Phase 1 clinical trials. About 30%
of the TEAEs were considered related to vaccination, and
these generally consisted of injection site reactions, with pain
being the most prevalent. Pruritus, erythema, and swelling
were reported much less frequently. The most common
related systemic reactions included headache, diarrhea, and
malaise. Sporadic abnormalities in laboratory test results,
most commonly hemoglobin changes, were reported after
vaccination in most volunteers but were not considered
clinicallysigniﬁcant,andtherewerenonotablechangesfrom
baseline through the end of each study (6 months after last
vaccination) within or across cohorts. There were no serious
adverse events (SAEs). The overall incidence of TEAEs and
the incidence of administration site reactions were higher in
the cohorts that received rBV A/B vaccine compared to the
cohorts that received antigens only in the rBV A/B-01 study.
Noapparentdosagerelationship wasseenacrosscohortsthat
received adjuvanted rBV A/B in either study.
In the rBV A/B-01 trial, at least 80% of volunteers vac-
cinated with the two highest dosages (20μga n d4 0μgt o t a l
immunizing protein) of rBV A/B developed sustained NAC
above the lower limit of quantitation for anti-BoNT/A1 and
anti-BoNT/B1antibodies.Theantigen-onlyformulationwas
not immunogenic. In the rBV A/B-01B trial, administration
of three doses of either 40μg or 100μg of rBV A/B vaccine
elicited detectable levels of neutralizing antibody for both
BoNT/A1andBoNT/B1inallvolunteers.Longervaccination
schedules (third vaccination given at Day 182) elicited a
greater NAC than shorter schedules (third vaccination given
at Day 56 or Day 112). Based on maximum NAC and
antibody kinetics, the vaccination schedule of Days 0, 28,
and 182 elicited the highest NAC levels, and there were no
signiﬁcant diﬀerences among dosages.
The rBV A/B-02 Phase 2 trial was a multicenter, blinded,
randomizedstudydesignedtoevaluatethesafety,tolerability,
and immunogenicity of a three-dose regimen (Days 0, 28,
182 and Days 0, 56, 182) of rBV A/B given at a single
dosage of 40μg total immunizing protein compared to saline
placebo. There were 440 volunteers in this study allocated to
2 cohorts of 165 subjects each that received rBV A/B and 2
c o h o rt so f5 5s u b j e ct se a c ht h a tr e c e i v e ds a l i n e .S u b j e ct sw e r e
followed up to 12 months after the last vaccination. Interim
data to 4 weeks after the last vaccination were analyzed; ﬁnal
data analysis is not yet complete.
Nearly all volunteers experienced at least one AE, with
approximately the same number among vaccine-treated and
placebo-treated volunteers. The majority of AEs were mild
or moderate in intensity, and there was no diﬀerence in
the overall incidence of TEAEs among treatment cohorts.
Three subjects were discontinued because of AEs that could
be related to vaccination (allergic dermatitis, erythema, and
swelling, all at the injection site). There were no SAEs related
to study vaccine. More volunteers treated with rBV A/B
reported injection site reactions compared to those treated
with placebo, the most common being pain, tenderness,
swelling, erythema, pruritus, and axillary pain. The most
common systemic reactions were headache, myalgia, arthral-
gia, feeling abnormal, fever, anxiety, malaise, and nausea.
Most TEAEs, however, were laboratory values outside the
normal range reported as AEs per the protocol. These
occurred in about 96% of subjects treated either with rBV
A/Borplacebo.ThemostfrequentlyreportedlaboratoryAEs
were hemoglobin decrease from baseline or increase from
baseline, with no signiﬁcant diﬀerence between treatment
cohorts. Most laboratory-related TEAEs were considered10 Advances in Preventive Medicine
mildormoderateinseverityandnotclinicallysigniﬁcantand
resolved without treatment.
The highest neutralizing antibody rates for both anti-
BoNT/A1 and anti-BoNT/B1 were observed at Day 210, 28
days after the last vaccine dose and were similar for both
vaccination schedules. Final data will evaluate the immune
response to one year after last vaccination.
5.6. Clinical Trials for rF1V. The rF1V vaccine was evaluated
in one Phase 1 (rF1V-01) and one Phase 2 (rF1V-02a)
clinical trial. A second Phase 2 (rF1V-02b) clinical trial is
ongoing. Male and female volunteers, age 18 to 40 years
in the rF1V-01 trial and 18 to 55 years in the rF1V-
02a trial, were recruited and assessed for eligibility after
signing an informed consent form. These studies were
conducted, monitored, and reviewed as described for rBV
A/B. The immune response to the vaccine was evaluated by
measurement of the concentration of antibodies to rF1, rV,
and rF1V by the Bridge ELISA at predetermined intervals
during the study and calculation of the seroconversion rate.
Blood was also collected for passive transfer studies for
evaluation of eﬃcacy in animals.
The ﬁrst trial, rF1V-01, was a single-center, open-label,
dosage-escalationstudydesigned toevaluatethesafety, toler-
ability, and immunogenicity of a two-dose regimen (Days 0
and28)ofrF1Vgivenatfourascendingdosages(20μg,40μg,
80μg, and 160μg total immunizing protein). Forty-four
subjects participated in the study, with 11 per cohort. Based
on analysis of the immunogenicity data, an extension study
evaluated the eﬀect of a third dose of 160μg administered
about230daysfollowingtheﬁrstdosein8of11subjectswho
had previously received the same vaccine dosage. All volun-
teers were followed for 180 days after the last vaccination.
All volunteers experienced at least one TEAE, and the
majority were either mild or moderate in intensity. Injection
site reactions were the most frequent related TEAEs and
were generally mild or moderate and more frequent at
the two highest dosages after two or three vaccinations.
The most common injection reactions were pain, swelling,
and erythema. Systemic reactions considered related to
vaccination were headache, fatigue, nausea, and diarrhea.
Most of these reactions were also mild or moderate and were
not considered clinically signiﬁcant. There were no clinically
signiﬁcant or related laboratory changes. After allowance
for the diﬀerent length of time between the vaccinations,
there was no apparent increase in the frequency of TEAEs
after the second or third vaccination compared to the ﬁrst
vaccination. Serial electrocardiograms were recorded after
the ﬁrst two doses in all cohorts, and no clinically signiﬁcant
abnormalities were observed.
The rF1V vaccine was immunogenic after two doses
of 20μg, 40μg, 80μg, or 160μg of vaccine. The antibody
response was markedly increased in volunteers who received
three doses of 160μg of vaccine, compared to their response
after two 160μg doses. Peak GMCs of all three antibodies
tested (anti-rF1, anti-rV and anti-rF1V) occurred 14 days
after the third dose. The administration of a third dose also
increased the rateof detectableantibody to allthreeantigens.
Based on this study, the two highest dosages (80μga n d
160μg) were selected for evaluation in the Phase 2a study in
a three-dose regimen.
The rF1V-02a Phase 2 trial was a multicenter, blinded
study designed to evaluate the safety, tolerability, and
immunogenicity of a three-dose regimen (Days 0, 28, and
182 and Days 0, 56, and 182) of rF1V given at two dosages
(80μg and 160μg total immunizing protein). There were 400
subjects (100 per cohort) in the study. Vaccinated subjects
were followed for 12 months after the last vaccination.
All subjects experienced at least one TEAE, and no
statistically signiﬁcant diﬀerence in overall incidence across
groups was observed. A total of six volunteers discontinued
due to a TEAE, two because of injection site reactions. The
majority of TEAEs were mild or moderate in intensity. There
were no SAEs related to study vaccine. Most volunteers had
TEAEs that occurred within 28 days following a vaccination,
and these were primarily injection site reactions. Most of
these reactions were mild or moderate in intensity, and
the most common were pain, swelling, erythema, and
pruritus. The most common related systemic reactions were
headache, malaise, nausea, and diarrhea. Most of these
reactions also were mild or moderate. The most common
laboratory abnormalities reported as AEs were increased
blood glucose and protein present in the urine and decreased
hemoglobin.TheseTEAEsweresporadic,notassociatedwith
other clinical abnormalities, and resolved without treatment.
In general, no clinically meaningful trends were noted in
changes to laboratory parameters in any vaccination group,
dosage, or schedule. Overall, the 80μg dosage had a slightly
better safety and tolerability proﬁle than the 160μgd o s a g e ,
and the Days 0, 56, and 182 schedule had a slightly better
safety and tolerability proﬁle than the Days 0, 28, and 182
schedule. In addition, there did not appear to be an increase
in the rate of either local or general TEAEs within 28 days
after vaccination with subsequent vaccinations.
The immunogenicity data indicate that GMCs for anti-
rF1, anti-rV, and anti-rF1V antibodies were much higher
after the third vaccination than after the second vaccination,
and almost all subjects had evidence of seroconversion 7
to 14 days after the last vaccination. The seroconversion
rate was indistinguishable among the selected dosage and
schedules following vaccination 3. Both groups that received
vaccination on the Days 0, 56, and 182 schedule showed
higher anti-rF1, anti-rV, and anti-rF1V GMCs and serocon-
version rates from 7 days after the second vaccination to
the prevaccination 3 assessment than groups that received
vaccination on the Days 0, 28, and 182 schedule. Based on
the results of this study, the 80μg dosage and the Days 0, 56,
182 vaccination schedule were selected for further testing in
the Phase 2b clinical trial. In addition, a shorter vaccination
schedule is being evaluated in the Phase 2b clinical trial to
assess whether or not equivalent immunogenicity is achieved
earlier by administering the third vaccination sooner.
Incompletedhumantrials,therF1Vvaccinewassafeand
well tolerated in the dosages and schedules used and elicited
an immunological response to the vaccine recombinant
antigen (rF1V) and to each of its components (rF1 and rV).Advances in Preventive Medicine 11
6. Plan for Bridging AnimalResponses to
PredictHumanEfﬁcacy
One of the most diﬃcult challenges of licensing vaccines
under the FDA Animal Rule is to bridge the animal and
human immune responses, demonstrating that the qualita-
tive and/or quantitative immune responses generated in the
animal studies are relevant to those observed in humans
and can be used to predict clinical beneﬁt and establish an
eﬀective dose. This requires a validated assay(s) that serves as
a correlate of protection to bridge animal and clinical data.
The challenges associated with this become signiﬁcant if the
mechanism(s) of immunity is not well understood, as is the
case for plague.
6.1. rBV A/B Program. The protective capacity of antibodies
speciﬁc for the BoNT was demonstrated in animals [19–23].
Much of the groundwork for elucidating neutralizing anti-
bodies as a correlate of protective immunity was performed
by Iakovlev in the 1950s, who demonstrated that passive
immunity provided to mice and guinea pigs was suﬃcient
to protect these animals from inhalational challenge of
serotype-speciﬁc BoNT [24]. The BoNT A/B NACs in sera
are assessed in a mouse (toxin) neutralizing antibody assay
(MNA) based on the Cardella method [25]. The NACs are
generally accepted as a measure of protection from exposure
to BoNT.
TheresultsofhumanstudiestodateindicatethattherBV
A/B vaccine is safe, well tolerated, and immunogenic. The
anti-BoNT NACs observed to be protective in animals will
be compared to the NACs observed in vaccinated humans
to predict clinical beneﬁt in humans (bridging). As noted
above, animal vaccine dosages were selected based on their
ability to induce NACs that are similar to those obtained
in the clinic, and those vaccine dosages and regimens will
be used to assess eﬃcacy in pivotal studies. Passive transfer
studies designed to be representative of the observed human
responses will be an important means of demonstrating
the ability of the rBV A/B vaccine to provide protection
to humans and for bridging the clinical and nonclinical
information.
6.2. rF1V Program. In contrast, there is no accepted assay
that correlates with protection from Y. pestis. Animals were
protected from pneumonic plague following vaccination
with the Y. pestis F1 and V antigens [26, 27]. F1 is a
17kDa protein that forms a capsule and may interfere with
complement-mediated opsonisation [26, 28]. The 37kDa
V virulence factor is a component of the Type 3 secretion
system known as the “Yop virulon.” The Yop virulon induces
apoptosisinhostphagocytesthroughtheinjectionofeﬀector
proteins from the bacterial cell. The V antigen is secreted
in response to environmental stimuli and is critical for
virulence [27, 29] independently and as a consequence of its
role in facilitating Yop eﬀector translocation.
TheF1andVantigensinducehumoralandcell-mediated
immune responses in mice, NHPs, and humans [7, 13, 30–
38]. The ability of the humoral responses to contribute to
rF1V coated on plate
Anti-rF1V
Biotin-rF1V
Streptavidin-HRP conjugate
TMB
Figure 3: Bridge ELISA schematic.
protectionfrombubonicandpneumonicplaguewasdemon-
strated with the passive transfer of F1-speciﬁc monoclonal
antibodies to mice. Likewise, V-speciﬁc antibodies protected
mice from aerosol challenge with F1+ and F1- strains of Y.
pestis [39, 40]. More recently, polyclonal and monoclonal
antibodies to rF1, rV, or rF1V protected na¨ ıve mice from
subcutaneous, intranasal, and aerosol exposure to Y. pestis,
[41,42] providing additional evidence ofa protective role for
antibodies.
Less is known about the role of cell-mediated immune
responses in providing protection from plague. Cytokines
secreted by T cells, including IFN-γ and TNF-α, which are
believed to activate phagocytes, restrict intracellular Y. pestis
replication, and facilitate the killing of intracellular bacilli
are being studied [37]. In addition, these cytokines appear
to contribute to protection by the humoral response, as
the neutralization of these cytokines in mice receiving sub-
optimal doses of F1- or V-speciﬁc antibody signiﬁcantly
reduced survival in these mice [38]. Blocking the cytokine
activity with cytokine-speciﬁc neutralizing antibodies also
interfered with protection in actively or passively vaccinated
mice challenged by the respiratory route with Y. pestis CO92
[43] .Ar o l ef o rI L - 1 7i np r o t e ct i o nf r o mY. pestis is also being
investigated [44].
Bridging the rF1V immune responses to predict clinical
beneﬁtis,therefore,morechallenging.Ashumoralresponses
areknowntobeinvolvedintheprotectionfromY. pestis,sev-
eral antibody-based assays are being considered to support
bridging. These include a Bridge ELISA (Figure 3), passive
transfer of antibodies, and a macrophage cytotoxicity assay.
6.3. Bridge ELISA. The Bridge ELISAs use rF1, rV, and rF1V
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vaccination, using a single standard curve that allows direct
comparison across clinical and nonclinical samples. The
assays are based on the capture of reactive antibodies in
immune sera using plates coated with his-F1, his-V, or his-
F1V antigen. The bound antibodies are detected by adding
diluted biotinylated antigen (rF1, rV, or rF1V) followed
by horseradish peroxidase-conjugated streptavidin solutions
and tetramethylbenzidine substrate. A chicken IgY standard
curve is used to quantitate the levels of antibody to rF1, rV,
and rF1V in the tested serum. A representation of the Bridge
ELISA forrF1V is presented inFigure 3, and the same format
is used for the rF1 and rV assays.
The key advantage of the Bridge ELISA over a standard
direct ELISA is that the same reagents are used across various
assays in a manner that has the capacity to be species neutral.
The advantage of species neutrality is that it avoids the
bias introduced by species-speciﬁc secondary reagents. A
limitation of the Bridge ELISA is that it is not a functional
assay that assesses the protective antibodies in the immune
sera but measures any antibody capable of binding the
antigen regardless of its protective capacity.
Titers measured in the Bridge ELISA are evaluated
statistically for correlation with survival data from direct
challenge studies in mice and CMs. Data obtained to
date indicate a continuing trend towards correlation with
survival, but the data from additional studies will be needed
to fully assess the utility of this assay as a correlate. Similarly,
the immunogenicity data from the Phase 2b trial will be
needed to analyze the human responses in light of the animal
titers and eﬃcacy.
6.4. Passive Transfer Studies. Passive transfer studies assess
thecombinedprotectivecapacityofantibodiestoF1andV.A
mousepassivetransfersystemwasusedpreviouslytosupport
a decision in 1941 to vaccinate military personnel under
serious threat of exposure to bubonic plague with killed
plague bacilli. The readout of the mouse passive transfer
assessed both percent mortality and time to death as a ratio
termed the Mouse Protection Index (MPI). Based on animal
data, MPI values were adopted as a reliable indicator for
predicting survival in nonclinical bubonic plague vaccine
eﬃcacy studies and to determine when booster vaccinations
were required in humans [45, 46].
The passive transfer system involves the administration
of immune sera from vaccinated animals or humans to
Y. pestis-na¨ ıve mice. Based on completed pharmacokinetic
studies, mice are exposed to aerosol challenge when serum
titers plateau. Results of completed CM-to-mouse passive
transfer assays demonstrate an association between humoral
immunity and protection against pneumonic plague. Results
of the survival analysis showed associations of antibody
levels with survival although no speciﬁc level of circulating
antibody (anti-rF1, anti-rV, or anti-rF1V) in either mouse
or donor serum has yet been deﬁned as providing a speciﬁc
level of protection. Mean survival time in the groups of mice
that received immune sera was greater than median survival
time in the control mice. The survival of the recipient
mice, the time to death, and the MPI are being evaluated
statistically for correlation with survival in direct aerosol
challenge studies in mice and CMs. Human sera from the
clinical trials are also being tested and evaluated statistically
in both the Bridge ELISA and in the passive transfer system
to bridge to the animal data.
6.5. Macrophage Cytotoxicity Assay. Y. pestis and the other
pathogenic species of Yersinia are cytotoxic for macrophages
and resistant to phagocytosis by cultured macrophages, but
the cytotoxicity and resistance can be neutralized by anti-V
antibodies. Several macrophage-based assays of immunity to
infection by Y. pestis were reported [47–51].
Y. pestis induces macrophage cell death through a
caspase-3-dependent apoptotic pathway. One test under
active investigation examines the ability of immune serum
from rF1V-vaccinated individuals to neutralize Yersinia-
induced macrophage cytotoxicity by measuring reduction in
caspase-3 levels. The key assay components include a mouse
macrophage-like cell line, J774A.1, Y. pseudotuberculosis (Y.
ptb [V]), where the endogenous V gene has been replaced
with the V gene from Y. pestis, serum samples from
immunized individuals, and the EnzChek caspase-3 II kit.
The kit uses a microtiter ﬂuorometric assay and a capsase-3-
speciﬁc substrate, Z-DEVD-R110, which is cleaved by active
caspase-3 to release the highly ﬂuorescent R110. This test is
beingevaluatedforitsfeasibilityasapotentialcorrelateassay.
Sera from rabbits vaccinated with V or rF1V were ﬁrst
evaluated to verify the ability of immune sera to neutral-
ize macrophage cytotoxicity and to quantitatively detect
diﬀerences in serum cytotoxicity-neutralizing activity. The
cytotoxicity assay was performed at USAMRIID as described
in detail previously [48], and a serum neutralization value
(NT50) determined. The NT50 values correspond to the
reciprocal of the serum dilution resulting in a 50% decrease
in caspase-3 levels. A good dose response was observed in
twofold titration assays as determined by regression analysis,
and the rabbit antisera yielded NT50 values ranging from
157 to 1384; there was no correlation between serum anti-
rV ELISA titers and NT50 values ([48], data not shown). The
results of preliminary evaluations in the macrophage assay
of sera from rF1V-vaccinated mice, macaques, and human
volunteers were highly suggestive of protection in the animal
or passive mouse transfer models.
6.6. Remaining Challenges for the rBV A/B and rF1V Devel-
opment Eﬀorts. The pivotal nonclinical studies and the
Phase 3 clinical trials that will be conducted following
manufacture of the conformance lots have signiﬁcant risks
associated with the ability to satisfy the FDA’s requirements
for licensure by the Animal Rule. The most signiﬁcant
technical challenges to be overcome prior to these pivotal
studies are successful manufacturing at commercial scale,
validation of processes and assays, and identifying a suitable
means for predicting clinical beneﬁt for rF1V. In addition
to the licensure requirements, the data generated during
the advanced development programs will need to satisfy the
DoD’s performance requirements.Advances in Preventive Medicine 13
7. Summary
Protection of the Nation’s warﬁghters and civilians is crucial
tothedefenseoftheUnitedStates.Oneofthethreatsfacedby
the warﬁghter and civilians is the oﬀensive use of biological
agents intended to either kill or incapacitate. Advanced
development eﬀorts for vaccines against botulinum neuro-
toxin and pneumonic plague are well on the way toward
achieving the performance and eﬃcacy objectives required
to advance to pivotal testing prior to applying for FDA
licensure.
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